Patient Leaflet Updated 09-Apr-2026 | Dr. Reddy's Laboratories (UK) Ltd
Nintedanib 100mg soft capsules
Nintedanib 100 mg soft capsules
nintedanib
Nintedanib 100 mg soft capsules will also be referred to in this leaflet as Nintedanib capsules.
1. What Nintedanib capsules are and what they are used for
2. What you need to know before you take Nintedanib capsules
3. How to take Nintedanib capsules
4. Possible side effects
5. How to store Nintedanib capsules
6. Contents of the pack and other information
Nintedanib capsules contain the active substance nintedanib, a medicine belonging to the class of so-called tyrosine kinase inhibitors, and it is used for the treatment of the following diseases:
IPF is a condition in which the tissue in your lungs becomes thickened, stiff and scarred over time. As a result, scarring reduces the ability to transfer oxygen from the lungs into the bloodstream and it becomes difficult to breathe deeply. Nintedanib capsules help to reduce further scarring and stiffening of the lungs.
Besides IPF, there are other conditions in which the tissue in your lungs becomes thickened, stiff, and scarred over time (lung fibrosis) and keeps worsening (progressive phenotype). Examples of these conditions are hypersensitivity pneumonitis, autoimmune ILDs (e.g. rheumatoid arthritis associated ILD), idiopathic nonspecific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. Nintedanib capsules help to reduce further scarring and stiffening of the lungs.
Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic autoimmune disease that affects connective tissue in many parts of the body. SSc causes fibrosis (scarring and stiffening) of the skin and other internal organs such as the lungs. When the lungs are affected by fibrosis, it is called interstitial lung disease (ILD), and so the condition is called SSc-ILD. Fibrosis in the lungs reduces the ability to transfer oxygen into the bloodstream, and breathing capacity is reduced. Nintedanib capsules help to reduce further scarring and stiffening of the lungs.
By blocking the activity of a group of proteins which are involved in the development of new blood vessels that cancer cells need to supply them with nutrition and oxygen, Nintedanib capsules can help stop the growth and spread of the cancer.
Nintedanib capsules are used in combination with another cancer medicine (docetaxel) to treat a cancer of the lung called non-small cell lung cancer (NSCLC). It is for adult patients whose NSCLC is of a certain type (“adenocarcinoma”) and who had already received one treatment with another medicine to treat this cancer but whose tumour started to grow again.
Talk to your doctor or pharmacist before taking this medicine
Based on this information your doctor may do some blood tests, for example to check your liver function and to determine how fast your blood can clot. Your doctor will discuss the results of these tests with you and decide whether you may receive Nintedanib capsules.
Inform your doctor immediately while taking this medicine
Nintedanib capsules should not be taken by children and adolescents under 18 years of age.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines and medicines obtained without a prescription.
Nintedanib capsules can interact with certain other medicines. The following medicines are examples that may increase the levels of nintedanib in your blood, and hence may increase the risk for side effects (see section 4):
The following medicines are examples that may lower the levels of nintedanib in your blood and thus may reduce the effectiveness of Nintedanib capsules:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Do not take this medicine during pregnancy, as it can harm your unborn baby and cause birth defects.
You must have a pregnancy test done to ensure you are not pregnant before starting treatment with Nintedanib capsules. Please talk to your doctor.
Contraception
Breast-feeding
Do not breast-feed during the treatment with Nintedanib capsules since there may be a risk of harm to the breast-fed child.
Fertility
The effect of this medicine on human fertility has not been investigated.
Nintedanib capsules may have minor influence on your ability to drive and use machines. You should not drive or use machines if you feel sick.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Take the capsules twice daily approximately 12 hours apart at about the same time every day, for example one capsule in the morning and one capsule in the evening. This ensures that a steady amount of nintedanib is maintained in your blood stream. Swallow the whole capsules with water and do not chew the capsules. It is recommended that you take the capsules with food, i.e. during or immediately before or after a meal. Do not open or crush the capsule (see section 5). For the ease of swallowing, you can take the capsules with a small amount (one teaspoonful) of cold or room temperature soft food, such as apple sauce or chocolate pudding. Swallow immediately and do not chew the capsule to ensure it stays intact.
Adults
The recommended dose is one capsule of 100 mg twice daily (a total of 200 mg per day). Do not take more than the recommended dose of two Nintedanib 100 mg capsules per day.
If you do not tolerate the recommended dose of two Nintedanib 100 mg capsules per day (see possible side effects in section 4), your doctor may advise you to stop taking this medicine. Do not reduce the dose or stop the treatment by yourself without consulting your doctor first.
Do not take Nintedanib capsules on the same day as your chemotherapy treatment with docetaxel.
Swallow the capsules whole with water and do not chew them. It is recommended to take the capsules with food, i.e. during or immediately before or after a meal. Do not open or crush the capsule (see section 5).
The recommended dose is four capsules per day (this is a total of 400 mg nintedanib per day). Do not take more than this dose.
This daily dose should be split into two doses of two capsules about 12 hours apart, for example two capsules in the morning and two capsules in the evening. These two doses should be taken at around the same time each day. Taking the medicine this way ensures that a steady amount of nintedanib is maintained in the body.
Dose reduction
If you cannot tolerate the recommended dose of 400 mg per day because of side effects (see section 4), your doctor may reduce the daily dose of Nintedanib capsules. Do not reduce the dose or stop the treatment yourself without consulting your doctor first.
Your doctor may reduce your recommended dose to 300 mg per day (two capsules of 150 mg). In this case your doctor will prescribe Nintedanib 150 mg soft capsules for your treatment.
If necessary, your doctor may further reduce your daily dose to 200 mg per day (two capsules of 100 mg). You will be prescribed the appropriate capsule strength by your doctor if this happens.
In both cases, you should take one capsule of the appropriate strength twice daily approximately 12 hours apart with food (for example in the morning and in the evening) at about the same time of the day.
In case your doctor has stopped your chemotherapy with docetaxel you should continue to take Nintedanib capsules twice daily.
Contact your doctor or pharmacist immediately.
Do not take a double dose if you have forgotten to take your earlier dose. You should take your next dose of Nintedanib capsules as planned at the next scheduled time recommended by your doctor or pharmacist.
Do not stop taking Nintedanib capsules without consulting your doctor first. It is important to take this medicine every day, as long as your doctor prescribes it for you.
Non-small cell lung cancer (NSCLC)
If you do not take this medicine as prescribed by your doctor, this cancer treatment may not work properly.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis associated interstitial lung disease (SSc-ILD)
You need to pay special attention if you get the following side effects during treatment with Nintedanib capsules:
Diarrhoea (very common, may affect more than 1 in 10 people)
Diarrhoea may lead to dehydration: a loss of fluid and important salts (electrolytes, such as sodium or potassium) from your body. At the first signs of diarrhoea drink plenty of fluids and contact your doctor immediately. Start appropriate anti-diarrhoeal treatment, e.g. with loperamide, as soon as possible.
The following other side effects were observed during treatment with this medicine.
Talk to your doctor if you get any side effects.
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Not known (cannot be estimated from the available data)
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Not known (cannot be estimated from the available data)
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Not known (cannot be estimated from the available data)
You need to pay special attention if you get the following side effects during treatment with Nintedanib capsules:
During treatment with Nintedanib capsules your doctor will regularly monitor your blood cells and examine you for signs of infection, such as inflammation, fever or tiredness.
The following side effects were observed under treatment with this medicine:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Not known (cannot be estimated from the available data)
If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the blister. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not use this medicine if you notice that the blister containing the capsules is opened or a capsule is broken.
If you are in contact with the content of the capsule, wash off your hands immediately with plenty of water (see section 3).
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Peach coloured, opaque, oblong, soft gelatin capsules (approx. 15 mm x 6 mm) filled with bright yellow coloured suspension and imprinted with “100” in black ink.
The capsules are available in blister and perforated unit dose blister in following pack-sizes:
30, 60 and 120.
Not all pack-sizes may be marketed.
This leaflet was last revised in September 2025.
Dr. Reddy's Laboratories (UK) Limited, 410 Cambridge Science Park, Milton Road, Cambridge, CB4 0PE, UK
+44 (0)1748 828 873
+44 (0)1223 651 475
+44 (0)1223 728 010
http://www.drreddys.com/united-kingdom